CVS Health Raises Full-Year Profit Guidance on Health Care Gains
The healthcare giant increased its full-year 2026 adjusted EPS guidance to a range of $7.90 to $8.10.
CVS Health (CVS), the healthcare services provider, reported a 35.4% year-over-year increase in consolidated adjusted operating income for the second quarter of 2026. The growth rate accelerated from the 12.5% increase recorded in the first quarter.
Total revenues rose 7.3% year-over-year to $106.1 billion. This represents an acceleration in growth compared to the 6.2% increase reported in the prior quarter.
Performance in the Health Care Benefits segment drove a significant portion of the results. Adjusted operating income for the segment increased 85.5% year-over-year, attributed to Government business performance and the absence of a $471 million premium deficiency reserve from the previous year. The segment's Medical Benefit Ratio improved to 87.4% from 89.9% in the prior year.
Revenue mix within the Health Care Benefits segment shifted during the quarter. Government business grew 9.9% year-over-year, while Commercial premium revenues declined 19.7%.
Health Services segment revenues increased 11.5% year-over-year, fueled by brand inflation and pharmacy drug mix. In the Pharmacy & Consumer Wellness segment, adjusted operating income rose 10.2%. Prescriptions filled on a 30-day equivalent basis increased 4.3%, aided by the acquisition of Rite Aid assets though partially offset by the September 2025 deconsolidation of Omnicare.
CVS raised its full-year 2026 guidance across several key metrics. Adjusted EPS guidance is now $7.90 to $8.10, up from a previous range of $7.30 to $7.50. GAAP diluted EPS guidance was raised to $6.84 to $7.04 from $6.24 to $6.44. The company also increased its cash flow from operations guidance to at least $11.5 billion from at least $9.5 billion.
During the quarter, the company launched a $29 MinuteClinic virtual visit service for the evaluation and prescription of GLP-1 therapy.